Return of lifetime caps scares chronic illness patients, physicians

The Affordable Care Act (ACA) did away with insurance companies imposing lifetime limits on how much it would spend on a customer’s care. With the law’s future in doubt, however, both patients and the physicians who treat them worry those caps may return.

The Tennessean examined the concerns from several angles. Stephen Patrick, MD, MPH, a neonatal physician at Vanderbilt University Medical Center, has seen the caps’ effects in his professional and personal life, when his mother exhausted her $100,000 limit on chemotherapy treatments less than two years after being diagnosed with cancer.

The return of high-risk pools, as advocated by House Republican leaders in their ACA alternatives, could also have lifetime limits. According to the Tennessean, risk pools in 33 states had lifetime limits ranging from between $1 and $2 million.

“When you look at $1 million, you may think that’s a lot, but, in reality, the cost of care is very expensive,” said Kevin Lucia, research professor at Georgetown University's Center on Health Insurance Reforms.

Read the full article below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup